# A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

> **NCT02256436** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 542 (actual)

## Conditions studied

- Urothelial Cancer

## Interventions

- **BIOLOGICAL:** pembrolizumab
- **DRUG:** paclitaxel
- **DRUG:** vinflunine
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT02256436
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-22
- **Primary completion:** 2016-09-07
- **Final completion:** 2020-10-01
- **Target enrollment:** 542 (ACTUAL)
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256436, "A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02256436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*